Foghorn Therapeutics Inc. FHTX
2.12 USD -0.01 (-0.57%)
Nov 3, 2026, 3:52 PM EST
2.08 Day range 2.20
1.79 52-week range 7.61
- YTD
- -60.78%
- 1 year
- -49.70%
Analyst view
Consensus: buy
Buy
Price target (mean) 12.00 +466.6% upside
Now 2.12
- Target (low)
- 4.00
- Target (mean)
- 12.00
- Target (high)
- 18.00
Ratings (0m) 7 6 buy · 1 hold · 0 sell
- Strong buy2
- Buy4
- Hold1
- Sell0
- Strong sell0
Recommendation trend
- This month 7
- 1 month ago 7
- 2 months ago 7
Earnings and revenue estimates
Consensus for the coming quarters and fiscal years
| Period | EPS estimate | Low – high | Year ago | EPS growth | Revenue estimate | Revenue growth | Analysts |
|---|---|---|---|---|---|---|---|
| Current quarter | -0.27333 | -0.33 – -0.23 | -0.57 | +52.0% | 8.14M | +41.0% | 3 |
| Next quarter | -0.24 | -0.24 – -0.24 | -0.59 | +59.3% | 5.45M | +7.9% | 1 |
| Current year | -1.56 | -1.79 – -1.35 | -2.34 | +33.3% | 29.65M | -13.2% | 5 |
| Next year | -1.11 | -1.82 – -0.75 | -1.56 | +28.7% | 32.94M | +11.1% | 5 |
Upgrades and downgrades
The latest rating changes
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 17, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Dec 16, 2024 | Jefferies | Maintained | Buy | Buy |
| Sep 24, 2024 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Sep 3, 2024 | Jefferies | Initiated | — | Buy |
| Aug 19, 2024 | Evercore ISI Group | Initiated | — | Outperform |
| Aug 12, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Aug 9, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| May 7, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 1, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Apr 10, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Apr 10, 2024 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Mar 8, 2024 | Wedbush | Reiterated | Outperform | Outperform |
| Nov 13, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Aug 7, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jul 6, 2023 | Morgan Stanley | Maintained | Equal-Weight | Equal-Weight |
| Jun 29, 2023 | Goldman Sachs | Maintained | Buy | Buy |
| Jun 28, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| Jun 8, 2023 | HC Wainwright & Co. | Reiterated | Buy | Buy |
| May 9, 2023 | Wedbush | Maintained | — | Outperform |
| May 9, 2023 | HC Wainwright & Co. | Maintained | — | Buy |
| Apr 25, 2023 | BMO Capital | Maintained | — | Outperform |
| Apr 25, 2023 | Wedbush | Maintained | — | Outperform |
| Mar 28, 2023 | B of A Securities | Initiated | — | Buy |
| Mar 10, 2023 | HC Wainwright & Co. | Reiterated | — | Buy |
| Mar 10, 2023 | Wedbush | Maintained | — | Outperform |
| Jan 5, 2023 | BMO Capital | Initiated | — | Outperform |
| Nov 21, 2022 | Morgan Stanley | Maintained | — | Equal-Weight |
| Aug 24, 2022 | Morgan Stanley | Downgrade | Overweight | Equal-Weight |
| Aug 10, 2022 | HC Wainwright & Co. | Maintained | — | Buy |
| May 24, 2022 | Goldman Sachs | Maintained | — | Buy |